One of the interesting features of the model is that it allows for an increased progression of metastatic cells to the avascular and the vascular stages immediately after surgery.
SCINIB subjects (5.0%) were more prevalent than AD preclinical stage 3 subjects (3.4%) and showed a trend for increased progression to MCI/DAT.
Because chondrocytes from two of thirteen different human donors responded to IL-1β with robust CHOP expression, it remains to be determined if increased CHOP expression in cartilage is a biomarker for increased progression in evolving OA.
Our study cannot differentiate between increased progression risks of HPV18 for the transition of CIN2/3 to SCC as an explanation of our findings, and underdetection of screen-diagnosed CIN2/3 lesions associated with HPV18 as an alternative theory.
Results of a trial in 666 women with advanced breast cancer, presented at the American Society of Clinical Oncology ASCOO) meeting in Chicago, showed the combination increased progression-free survival for a median 24.8 months compared with 14.5 months for letrozole alone.
When combined with chemotherapy in the drug's critical phase III trial, Avastin increased progression-free survival for the average metastatic breast cancer patient by 5.5 months.
With proven efficacy in terms of remission rates as well as increased progression-free survival for all MDS subtypes and improved overall survival in higher-risk MDS, azacitidine now represents the best alternative therapeutic option for those higher-risk MDS patients not eligible for allogeneic SCT.
Second, optimal debulking was associated with increased progression-free survival (PFS) mainly for patients with less extensive disease at the outset.
The addition of pertuzumab, an anti-HER2 monoclonal antibody, to trastuzumab and docetaxel therapy significantly increases progression-free survival (PFS) for patients with HER2-positive metastatic breast cancer (median PFS, 19.5 versus 12.4 months) [ 15].
In models adjusted for age, sex, ethnicity, MESA site, years in between scans, and log(baseline CAC), there were significantly increased CAC progression rates for the 3rd (β = 9.4, 95% CI 2.2 16.6) and 4th (β = 11.5, 95% CI 4.5 18.4) quartiles compared with the 1st quartile.
